Biogen (BIIB) Tops Q3 EPS by 61c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Strong AI earnings lift S&P 500, Nasdaq as inflation data calms rate-hike jitters
- Oil prices little changed as investors weigh lower demand against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Biogen (BIIB) PT Raised to $355 at Leerink Partners
October 25, 2017 7:29 AM EDTLeerink Partners raised its price target on Biogen (NASDAQ: BIIB) to $355.00 (from $351.00) while maintaining a Market Perform rating.
... MoreBiogen (BIIB) Reports AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
October 25, 2017 5:56 AM EDTBiogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis (MS). The trial follows the comprehensive review of SYNERGY, a Phase 2 trial, which identified a specific population that may be more likely to respond to treatment.
These data... More
BMO Capital Upgrades Biogen (BIIB) to Outperform
October 25, 2017 1:01 AM EDTBMO Capital upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $381.00 (from $382.00).
Analyst Ian Somaiya says the MS thesis is playing out. The analyst is not "calling the bottom on BIIB" noting the MS franchise estimate... More
SPINRAZA Confusion Creates a Buying Opportunity in Biogen (BIIB) - Stifel
October 24, 2017 11:58 AM EDTStifel analyst Thomas Shrader reiterated a Buy rating and $430 price target on Biogen (NASDAQ: BIIB) saying SPINRAZA confusion is an opportunity.
"Some SPINRAZA confusion based in flattish U.S. sales in the face of 75% patient number increase," Shrader commented. "We expect the 2Q revenue... More
